Transplantation outcome according to malignancy risk factors
| Risk level§ . | UPN . | Age/sex . | Malignancy characteristics* . | GVHD† . | Overall outcome‡ . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study entry . | Pre-HCT . | Acute . | Late acute . | Chronic . | ||||||||||||
| Dx . | # . | Res . | Res . | NED . | s . | g . | l . | Gr . | Tumor . | Survival . | Death . | |||||
| 3 | 3 | 44/F | AML | 4 | S | hCR | N | 0 | 0 | 0 | 0 | tr | Y (o, s, v) | PD | N | 748 (PD) |
| 4 | 47/M | AML | 2 | S | PD | N | 2 | 1 | 0 | 2 | (n.e.) | (n.e.) | PD | N | 119 (PD) | |
| 6 | 67/M | DLC | 5 | R | PD | N | 1 | 0 | 0 | 1 | (n.e.) | (n.e.) | PD | N | 91 (PD) | |
| 7 | 24/M | AML | 3 | S | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 194 (PD) | |
| 9 | 32/M | HD | 5 | R | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 1004 (PD) | |
| 14 | 52/F | A-TCL | 4 | 1° R | PD | N | 0 | 0 | 0 | 0 | tr | Y (o, s, v, e) | CR | + 1669 | n.a. | |
| 15 | 30/M | DLC-EBV | 2 | 1° R | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 328 (PD) | |
| 16 | 59/M | AML | 3 | S | hCR | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 386 (PD) | |
| 19 | 42/F | HD | 3 | 1° R | SD | N | 0 | 0 | 0 | 0 | 0 | Y (s) | CR | + 1563 | n.a. | |
| 21 | 44/F | DLC (trFL) | 4 | S | SD | N | 0 | 0 | 0 | 0 | tr | Y (s) | CR | + 1514 | n.a. | |
| 23 | 60/F | DLC | 5 | R | PD | N | 0 | 0 | 0 | 0 | tr, g, s | N | PD | N | 192 (PD) | |
| 24 | 43/F | DLC | 5 | R | PD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 170 (PD) | |
| 25 | 33/M | NHL-GZ | 3 | R | PD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 268 (PD) | |
| 26 | 23/M | HD | 4 | R | SD | N | 0 | 0 | 0 | 0 | 0 | Y (s) | PD | N | 1024 (PD) | |
| 27 | 39/F | CML | 4 | R | hCR | N | 0 | 0 | 0 | 0 | tr | N | mCR | + 1457 | n.a. | |
| 28 | 66/M | DLC (trCLL) | 3 | R | SD | N | 0 | 2 | 0 | 3 | (n.e.) | (n.e.) | PD | N | 92 (PD) | |
| 29 | 47/M | A-TCL | 5 | S | CR | Y | 1 | 0 | 0 | 1 | 0 | Y (s, l) | CR | + 1402 | n.a. | |
| 31 | 27/F | HD | 2 | S | SD | N | 0 | 0 | 0 | 0 | g | Y (s, o) | CR | + 1355 | n.a. | |
| 34 | 45/M | NHL-GZ | 4 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1325 | n.a. | |
| 36 | 49/F | DLC | 2 | S | PR | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 234 (PD) | |
| 37 | 52/M | DLC (trFL) | 4 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1299 | n.a. | |
| 38 | 58/M | NHL-pDC | 1 | 1° R | CR | Y | 0 | 0 | 0 | 0 | 0 | Y (o, s, e) | PD | N | 525 (PD) | |
| 39 | 55/F | DLC (trFL) | 3 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1285 | n.a. | |
| 40 | 69/M | CML | 4 | R | SD | N | 0 | 0 | 0 | 0 | 0 | N | SD | + 1272 | n.a. | |
| Risk level§ . | UPN . | Age/sex . | Malignancy characteristics* . | GVHD† . | Overall outcome‡ . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study entry . | Pre-HCT . | Acute . | Late acute . | Chronic . | ||||||||||||
| Dx . | # . | Res . | Res . | NED . | s . | g . | l . | Gr . | Tumor . | Survival . | Death . | |||||
| 3 | 3 | 44/F | AML | 4 | S | hCR | N | 0 | 0 | 0 | 0 | tr | Y (o, s, v) | PD | N | 748 (PD) |
| 4 | 47/M | AML | 2 | S | PD | N | 2 | 1 | 0 | 2 | (n.e.) | (n.e.) | PD | N | 119 (PD) | |
| 6 | 67/M | DLC | 5 | R | PD | N | 1 | 0 | 0 | 1 | (n.e.) | (n.e.) | PD | N | 91 (PD) | |
| 7 | 24/M | AML | 3 | S | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 194 (PD) | |
| 9 | 32/M | HD | 5 | R | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 1004 (PD) | |
| 14 | 52/F | A-TCL | 4 | 1° R | PD | N | 0 | 0 | 0 | 0 | tr | Y (o, s, v, e) | CR | + 1669 | n.a. | |
| 15 | 30/M | DLC-EBV | 2 | 1° R | SD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 328 (PD) | |
| 16 | 59/M | AML | 3 | S | hCR | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 386 (PD) | |
| 19 | 42/F | HD | 3 | 1° R | SD | N | 0 | 0 | 0 | 0 | 0 | Y (s) | CR | + 1563 | n.a. | |
| 21 | 44/F | DLC (trFL) | 4 | S | SD | N | 0 | 0 | 0 | 0 | tr | Y (s) | CR | + 1514 | n.a. | |
| 23 | 60/F | DLC | 5 | R | PD | N | 0 | 0 | 0 | 0 | tr, g, s | N | PD | N | 192 (PD) | |
| 24 | 43/F | DLC | 5 | R | PD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 170 (PD) | |
| 25 | 33/M | NHL-GZ | 3 | R | PD | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 268 (PD) | |
| 26 | 23/M | HD | 4 | R | SD | N | 0 | 0 | 0 | 0 | 0 | Y (s) | PD | N | 1024 (PD) | |
| 27 | 39/F | CML | 4 | R | hCR | N | 0 | 0 | 0 | 0 | tr | N | mCR | + 1457 | n.a. | |
| 28 | 66/M | DLC (trCLL) | 3 | R | SD | N | 0 | 2 | 0 | 3 | (n.e.) | (n.e.) | PD | N | 92 (PD) | |
| 29 | 47/M | A-TCL | 5 | S | CR | Y | 1 | 0 | 0 | 1 | 0 | Y (s, l) | CR | + 1402 | n.a. | |
| 31 | 27/F | HD | 2 | S | SD | N | 0 | 0 | 0 | 0 | g | Y (s, o) | CR | + 1355 | n.a. | |
| 34 | 45/M | NHL-GZ | 4 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1325 | n.a. | |
| 36 | 49/F | DLC | 2 | S | PR | N | 0 | 0 | 0 | 0 | 0 | N | PD | N | 234 (PD) | |
| 37 | 52/M | DLC (trFL) | 4 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1299 | n.a. | |
| 38 | 58/M | NHL-pDC | 1 | 1° R | CR | Y | 0 | 0 | 0 | 0 | 0 | Y (o, s, e) | PD | N | 525 (PD) | |
| 39 | 55/F | DLC (trFL) | 3 | S | CR | Y | 0 | 0 | 0 | 0 | 0 | N | CR | + 1285 | n.a. | |
| 40 | 69/M | CML | 4 | R | SD | N | 0 | 0 | 0 | 0 | 0 | N | SD | + 1272 | n.a. | |
A-TCL, anaplastic T-cell NHL; CLL, chronic lymphocytic leukemia; DLC, diffuse large cell; DLC-EBV, Epstein-Barr virus–driven DLC; DLC (trCLL), CLL transformed to DLC; DLC (trFL), transformed follicular NHL to DLC; Dx, diagnoses; F, female; HD, Hodgkin disease; M, male; N, no; n.a., not applicable; n.e., not evaluable; NED, no evidence of disease status; NHL-GZ, gray-zone NHL; NHL-pDC, plasmablastic dendritic cell NHL; UPN, unique patient number; Y, yes.
#, number of prior regimens. Res, disease response to last prior regimen: S, sensitive; R, refractory; 1° R, primary refractory. Pre-HCT, indicates disease status at time of low-intensity transplant: Res, response to EPOCH-F(R): PR, partial response; CR, complete response; SD, stable disease; hCR, hematologic CR; and PD, progressive disease.
Acute GVHD score of skin (s), gut (g), and liver (l); Gr, overall grade (0-4). Late acute GVHD, manifested as elevated liver transaminase levels (tr), skin (s), or gut involvement (g). Chronic GVHD sites of involvement: oral (o), skin (s), eye (e), vaginal (v), and lung (l).
Overall outcome for last tumor staging: PD, progressive disease; CR, complete remission; mCR, molecular CR; and SD, stable disease. Ongoing survival, in days post-HCT (+). Death, day post-HCT; cause due to PD.
Risk of progressive disease post-HCT: level 3, high risk.